フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in...
January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...
November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3...
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication...
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on...
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa...
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod...
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo...
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約